29 results about "Hybrid protein" patented technology

The invention discloses a method for extracting bilirubin, cholic acid and chenodeoxycholic acid from chicken bile. The method comprises the steps of pretreatment, chicken bile treatment, hydrolysis reduction, chromatographic separation and the like. The method comprises the following steps: slicing frozen chicken gallbladder, heating, unfreezing and melting to denature protein into solid, then cooling, performing three-phase centrifugal degreasing and deproteinization, and adding three enzymes including biliverdin reductase, coenzyme I and glucose dehydrogenase to reduce free biliverdin and combined biliverdin, so as to obtain the biliverdin-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase. The method comprises the following steps: adding cholic acid and chenodeoxycholic acid into a container, adding gluconic acid hydrolase and bile salt hydrolase to hydrolyze biliverdin and bile acid, adding trypsin to hydrolyze impure protein, performing chromatography by using macroporous silica gel, and separating bilirubin, cholic acid and chenodeoxycholic acid by using different molecular space structures to obtain high-purity bilirubin, cholic acid and chenodeoxycholic acid. The method has the advantages of simple process, few types of used solvents, low toxicity, and facilitation of environmental protection and industrial production.

The present invention describes an approach for improving immunogenic and therapeutic performance in the prevention and / or treatment of lesions and / or cancer caused by or associated with the human papillomavirus (HPV). More specifically, the approach involves a hybrid protein selected from two entities with improved immunogenic and therapeutic potential, use thereof and a formulation comprising same. Also disclosed are nucleotide sequences, a vector for the expression of recombinant proteins, as well as a process for producing a formulation comprising said entity and a therapeutic method. The invention applies to the fields of medicine, pharmacy and biotechnology.

A hybrid protein containing a CFH functional unit and a DAF functional unit, a mutant thereof, a nucleic acid encoding the hybrid protein, a method for treating a disease or condition associated with the complement system, and a use thereof, as well as a fusion protein constructed based on the hybrid protein mutant and an antibody that specifically binds to complement C5. Further provided are a polynucleotide encoding the fusion protein, an expression vector, and a host cell, pharmaceutical compositions thereof, and a method for treating a disease associated with C5 protein, and a use thereof.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The invention relates to genetic and protein engineering and can be used in medicine and the pharmaceutical industry. Recombinant plasmid DNA pET23b-CBD-HS-ES-GLP1, pET-parB-CBD-HS-ES-GLP1 and pET23bKanR-CBD-HS-ES-GLP1 were constructed to provide the synthesis of a hybrid protein containing the GLP-1 polypeptide sequence in Escherichia coli cells. By transforming the E. coli BL21 (DE3) strain with plasmids pET23b-CBD-HS-ES-GLP1, pET-parB-CBD-HS-ES-GLP1 and pET23bKanR-CBD-HS-ES-GLP1, the CBD-HS-ES-GLP1 hybrid protein has been produced. A method of producing polypeptide GLP-1 has been developed, which involves preparing and cultivating a producer of a hybrid protein containing polypeptide GLP-1, followed by isolation and cleavage of the said hybrid protein. The invention enables the production of polypeptide GLP-1 with high yield and simplified technology.

Provided are a hybrid protein comprising a CFH functional unit and a DAF functional unit, an encoding nucleic acid thereof, and a method and use thereof for treating related diseases or disorders of a complement system.

A method may include applying a protein sequence calculation model to generate a plurality of proposed protein sequences based on an input protein sequence. A set of possible amino acid residues for each position in at least a portion of the output protein sequence may be identified based on the plurality of proposed protein sequences. A first protein structure having the output protein sequence may be generated by applying a protein structure calculation model to select an amino acid residue from a corresponding set of possible amino acid residues for each location in at least the portion of the output protein sequence. The protein structure calculation model may further determine a conformation of the amino acid residues selected for inclusion in the output protein sequence. In some cases, the first protein structure may be grafted onto a second protein structure to form a third protein structure.

Provided are biodegradable 3D porous hybrid protein (3D-PHP) nanoscaffolds that comprise MnO2 nanosheets and avoid covalent modification of proteins. These nanoscaffolds demonstrate inflammatory stimuli-responsive drug release as well as disc-mimetic stiffness. Also provided are methods of using (e.g., treating intervertebral disc disease (IVDD)) and manufacturing such nanoscaffolds.

The present invention relates to a hybrid protein comprising a urokinase catalytic domain and a VHH specifically binding to vWF for use in treating a patient having elevated serum lactate dehydrogenase (LDH) levels or at risk thereof following or during a traumatic event. The treatment comprises administering the hybrid protein to reduce the serum LDH levels of the patient to a target range of less than 280 U / L. The present invention also relates to means and methods for the prevention and / or treatment (including, as mentioned herein, reducing and / or limiting the damage caused by) of tissue damage, especially tissue damage associated with the occurrence and / or formation of thrombi in circulation.

The invention relates to recombinant RE15mR and EJ17zipR hybrid proteins with the structure specified in the description, recombinant DNA sequences encoding recombinant hybrid proteins, vectors containing recombinant DNA sequences, as well as eukaryotic or prokaryotic expression systems transformed with recombinant DNA sequences. The invention also concerns the use of recombinant hybrid proteins as components of bioink intended for bioprinting, and also as components of biomaterials. Furthermore, the invention relates to the use of recombinant DNA sequences, vectors and eukaryotic or prokaryotic expression systems for the production of recombinant hybrid proteins.

Are disclosed peptide binding the CD71 transferring receptor, genetically engineered DNA-binding proteins from starved cells (DPS), and hybrid protein-nucleic acid complexes having the capability of being identified and taken up by the human CD71 receptor, and which can be used in targeted delivery of nucleic acid in cells.

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

Provided are a hybrid protein comprising a CFH functional unit and a DAF functional unit. an encoding nucleic acid thereof, and a method and use thereof for treating related diseases or disorders of a complement system.

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

Disclosed are methods of making recombinant secretion of silk and collagen proteins, and amyloid fusions thereof, using bacteria.

Provided is a vector library for yeast two-hybrid screening of a deubiquitinating enzyme that binds to a target protein and a method for identifying a deubiquitinating enzyme binding to a target protein using the same. Further provided is a method for screening an agent having anti-cancer activity targeting the deubiquitinating enzyme USP1, USP7, USP12, or USP49 identified by the identifying method.

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

A method may include applying a protein sequence computation model to generate, based on an input protein sequence, a plurality of proposed protein sequences. A set of possible amino acid residues for each position in at least a portion of an output protein sequence may be identified based on the plurality of proposed protein sequences. A first protein structure having the output protein sequence may be generated by applying a protein structure computation model to select, for each position in at least the portion of the output protein sequence, an amino acid residue from a corresponding set of possible amino acid residues. The protein structure computation model may further determine the conformation of the amino acid residues selected for inclusion in the output protein sequence. In some cases, the first protein structure may be grafted onto a second protein structure to form a third protein structure.

The present disclosure provides cytokine hybrid proteins such as IL2-IL15 cytokine hybrid proteins. The present disclosure further provides nucleic acids and vectors encoding such cytokine hybrid proteins and cells comprising such nucleic acids. Further provided are pharmaceutical compositions, therapeutic methods, and manufacturing methods relating to such cytokine hybrid proteins.

The present invention provides means and methods for treating MVT and associated and / or similar conditions. The invention therefore provides hybrid proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The invention further provides therapeutic methods for conditions that can be prevented or treated by local delivery / stimulation of plasminogen activation to sites of microvascular occlusion.

The present disclosure provides cytokine hybrid proteins such as IL2-IL15 cytokine hybrid proteins. The present disclosure further provides nucleic acids and vectors encoding such cytokine hybrid proteins and cells comprising such nucleic acids. Further provided are pharmaceutical compositions, therapeutic methods, and manufacturing methods relating to such cytokine hybrid proteins.

The invention provides a mixed protein base material and application thereof, and the mixed protein base material comprises the following components in percentage by mass: 25%-80% of whey protein, 15%-70% of collagen peptide, 2%-4% of moderately hydrolyzed whey protein, 1%-2% of highly hydrolyzed whey protein and 2%-4% of whey protein rich in milk phospholipid membrane. According to the mixed protein base material provided by the invention, an oil-water interface of an emulsion is jointly stabilized through proteins with different molecular weights and compositions, the emulsion and microcapsules can be effectively stabilized, and fat-soluble functional factors are further delivered by utilizing the obtained emulsion and microcapsules, so that the stability of the fat-soluble functional factors can be improved; and the bioavailability can be improved.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The invention relates to a recombinant RE15mR and EJ17zipR hybrid protein with a structure as described in the specification, a recombinant DNA sequence for coding the recombinant hybrid protein, a vector containing the recombinant DNA sequence, and a eukaryotic or prokaryotic expression system transformed by using the recombinant DNA sequence. The invention also relates to the use of the recombinant hybrid protein as a component of bio-inks intended for bio-printing and as a component of biological materials. In addition, the invention also relates to the use of the recombinant DNA sequence, the vector and the eukaryotic or prokaryotic expression system for preparing the recombinant hybrid protein.

The present invention relates to preventive and therapeutic vaccines against HPV and cancers associated with the virus, which are intended for use in people seeking prevention or those who have developed cancer and have been infected with HPV. The present invention also relates to DNA expression vectors that are capable of effectively producing the capsid protein L2 of the HPV16 virus, and also the viral oncoprotein E6 associated with human papillomavirus tumors. In particular, the present invention relates to recombinant fusion or hybrid proteins obtained by gene cloning into expression vectors, which are produced by gene translation of a fusion gene formed by combining the nucleic acid regulatory sequences of one or more genes with the protein coding sequences of one or more genes, and which are used to generate two different types of responses: a long-lasting humoral immune response that can stimulate the production of specific anti-L2 and anti-E6 antibodies against HPV (preventive effect), and the activation of a cellular immune response to fight tumor cells and induce the expression of the cytokine TNF (tumor necrosis factor) (therapeutic effect).

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The present invention discloses a technical field involving antibiotic enzymes, and in particular, relates to a hybrid antibiotic enzyme for killing animal-derived pathogens and its application. The hybrid antibiotic enzyme includes a hybrid protein E1C1, and the hybrid protein E1C1 includes a catalytic domain E1 as shown in SEQ ID NO:2 and a binding domain C1 as shown in SEQ ID NO:3. The present invention also provides an application of a hybrid antibiotic enzyme in the preparation of a pharmaceutical composition for controlling microbial infection, and a pharmaceutical composition comprising the hybrid antibiotic enzyme as an effective ingredient. The hybrid antibiotic enzyme of the present application can quickly lyse common animal-derived pathogens Escherichia coli, Salmonella, Staphylococcus aureus and Helicobacter pylori, and can also efficiently kill common pathogens such as clinically isolated Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.

The present invention relates to a recombinant hybrid protein, a nucleic acid molecule encoding the recombinant hybrid protein, a gene transfer expression cassette containing the nucleic acid molecule, and a gene delivery system containing the gene transfer expression cassette, which can be used to treat muscular dystrophy. The nucleic acid molecule, gene transfer expression cassette, and gene delivery system of the present invention can stably express a therapeutic protein in muscle tissue, and achieve good therapeutic effects on muscular dystrophy.